Search

Author/Creator de la Torre, Inmaculada

1. 9G4 expression on autoantibodies to citrullinated peptides in patients with early inflammatory arthritis and established rheumatoid arthritis. (22nd February 2012)

Authors:
Moura, Rita A; de la Torre, Inmaculada; Leandro, Maria J; Edwards, Jonathan C W; Fonseca, João E; Cambridge, Geraldine
Journal:
Annals of the rheumatic diseases
Issue:
Volume 71(2012)Supplement 1
Page Start:
A24
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A1.25 B-Cell profile in RA patients treated with two different biological therapeutic targets: anti-TNF and anti-IL6R. a cross-sectional study. (31st January 2014)

Authors:
Hernández, Diana; Valor, Lara; de la Torre, Inmaculada; del Río, Tamara; Martinez, Lina; Naredo, Esperanza; González, Carlos; Lopez-Longo, Javier; Monteagudo, Indalecio; Montoro, María; Carreño, Luis
Journal:
Annals of the rheumatic diseases
Issue:
Volume 73:Supplement 1(2014)
Page Start:
A10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A1.26 Establishing cut-off of infliximab levels and anti-infliximab antibodies by commercial elisa in patients with rheumatoid arthritis. (31st January 2014)

Authors:
Hernández, Diana; Valor, Lara; de la Torre, Inmaculada; Martínez, Lina; Carlos Nieto, Juan; del Río, Tamara; Naredo, Esperanza; González, Carlos; López-Longo, Javier; Montoro, María; Monteagudo, Indalecio; Carreño, Luis
Journal:
Annals of the rheumatic diseases
Issue:
Volume 73:Supplement 1(2014)
Page Start:
A11
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Issue 12 (25th June 2010)

Authors:
de la Torre, Inmaculada; Moura, Rita A; Leandro, Maria J; Edwards, Jonathan; Cambridge, Geraldine
Journal:
Annals of the rheumatic diseases
Issue:
Volume 69:Issue 12(2010)
Page Start:
2181
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Issue 10381 (25th March 2023)

Authors:
Morand, Eric F; Vital, Edward M; Petri, Michelle; van Vollenhoven, Ronald; Wallace, Daniel J; Mosca, Marta; Furie, Richard A; Silk, Maria E; Dickson, Christina L; Meszaros, Gabriella; Jia, Bochao; Crowe, Brenda; de la Torre, Inmaculada; Dörner, Thomas
Journal:
Lancet
Issue:
Volume 401:Issue 10381(2023)
Page Start:
1001
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Issue 5 (22nd February 2022)

Authors:
Lopez-Romero, Pedro; de la Torre, Inmaculada; Haladyj, Ewa; Aletaha, Daniel; Smolen, Josef S
Journal:
Annals of the rheumatic diseases
Issue:
Volume 81:Issue 5(2022)
Page Start:
622
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Issue 1 (29th September 2016)

Authors:
Dougados, Maxime; van der Heijde, Désirée; Chen, Ying-Chou; Greenwald, Maria; Drescher, Edit; Liu, Jiajun; Beattie, Scott; Witt, Sarah; de la Torre, Inmaculada; Gaich, Carol; Rooney, Terence; Schlichting, Douglas; de Bono, Stephanie; Emery, Paul
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76:Issue 1(2017)
Page Start:
88
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. Issue 3 (6th October 2020)

Authors:
Kay, Jonathan; Harigai, Masayoshi; Rancourt, Josh; Dickson, Christina; Melby, Thomas; Issa, Maher; de la Torre, Inmaculada; Isaka, Yoshitaka; Cardoso, Anabela; Saifan, Chadi; Keystone, Edward C; van Vollenhoven, Ronald F; Giles, Jon T; Huizinga, Tom WJ; Kremer, Joel M
Journal:
RMD open
Issue:
Volume 6:Issue 3(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Issue 2 (7th September 2018)

Authors:
Takeuchi, Tsutomu; Genovese, Mark C; Haraoui, Boulos; Li, Zhanguo; Xie, Li; Klar, Rena; Pinto-Correia, Ana; Otawa, Susan; Lopez-Romero, Pedro; de la Torre, Inmaculada; Macias, William; Rooney, Terence P; Smolen, Josef S
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78:Issue 2(2019)
Page Start:
171
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Issue 2 (9th February 2019)

Authors:
Takeuchi, Tsutomu; Genovese, Mark C; Haraoui, Boulos; Li, Zhanguo; Xie, Li; Klar, Rena; Pinto-Correia, Ana; Otawa, Susan; Lopez-Romero, Pedro; de la Torre, Inmaculada; Macias, William; Rooney, Terence P; Smolen, Josef S
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78:Issue 2(2019)
Page Start:
171
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗